Condition: HIV Infections · Sponsor: Radboud University Medical Center
Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy are available. As the changes in pharmacokinetics during pregnancy are most prominent in the third trimester a pharmacokinetic curve will be recorded in the third trimester after attaining steady state.
This description comes directly from the study's public registry record.
David M Burger, PharmD PhD · ++31 24 3616405 · david.burger@radboudumc.nl
Wendy van der Wekken, MSc
Always discuss trial participation with your own doctor first.
| Saint-Pierre University Hospital; Department of Infectious Diseases | Brussels, Belgium | Recruiting |
| CHARITÉ Berlin | Berlin, Germany | Recruiting |
| University of Bonn | Bonn, Germany | Recruiting |
| University of Cologne | Cologne, Germany | Recruiting |
| Johann Wolfgang Goethe-Universität | Frankfurt am Main, Germany | Recruiting |
| University München | München, Germany | Recruiting |
| Mater Hospital and UCD | Dublin, Ireland | Recruiting |
| St James's Hospital Dublin | Dublin, Ireland | Recruiting |
| IRCSS | Rome, Italy | Completed |
| AMC | Amsterdam, Netherlands | Completed |
| Radboud University Nijmegen Medical Centre | Nijmegen, Netherlands | Recruiting |
| Erasmus Medical Center Rotterdam | Rotterdam, Netherlands | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00825929